J. William Lindsey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
J. William Lindsey has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
F. Nelson
2 shared publicationsH. Phuong T. Pham
Division of Multiple Sclerosis and Neuroimmunology, Department of Neurology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030
2 shared publicationsJ.S. Wolinsky
2 shared publicationsLandon M. Hatfield
2 shared publicationsS. Patel
Department of Neurology, University of Texas Health Science Center at Houston, TX, USA
2 shared publicationsAmy Pruitt
Department of Neurology, University of Pennsylvania Medical Center, Philadelphia, PA, USA
1 shared publication
Latest Publications
- 24 November 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 105, 106884
Epstein-Barr virus and multiple sclerosis: A mechanism comes into focus
- 24 November 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 105, 106884
Epstein-Barr virus and multiple sclerosis: A mechanism comes into focus
- Top Cited PapersOpen Access
- 8 January 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (3)
Expanded T lymphocytes in the cerebrospinal fluid of multiple sclerosis patients are specific for Epstein-Barr-virus-infected B cells
Epstein–Barr virus (EBV) infection has long been associated with multiple sclerosis (MS), but the role of EBV in the pathogenesis of MS is not clear. Our hypothesis is that a major fraction of the expanded clones of T lymphocytes in the cerebrospinal fluid (CSF) are specific for autologous EBV-infected B cells. We obtained blood and CSF samples from eight relapsing-remitting patients in the process of diagnosis. We stimulated cells from the blood with autologous EBV-infected lymphoblastoid cell lines (LCL), EBV, varicella zoster virus, influenza, and candida and sorted the responding cells with flow cytometry after 6 d. We sequenced the RNA for T cell receptors (TCR) from CSF, unselected blood cells, and the antigen-specific cells. We used the TCR Vβ CDR3 sequences from the antigen-specific cells to assign antigen specificity to the sequences from the CSF and blood. LCL-specific cells comprised 13.0 ± 4.3% (mean ± SD) of the total reads present in CSF and 13.3 ± 7.5% of the reads present in blood. The next most abundant antigen specificity was flu, which was 4.7 ± 1.7% of the reads in the CSF and 9.3 ± 6.6% in the blood. The prominence of LCL-specific reads was even more marked in the top 1% most abundant CSF clones with statistically significant 47% mean overlap with LCL. We conclude that LCL-specific sequences form a major portion of the TCR repertoire in both CSF and blood and that expanded clones specific for LCL are present in MS CSF. This has important implications for the pathogenesis of MS.
- 8 January 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (3)
Top Cited PapersOpen AccessExpanded T lymphocytes in the cerebrospinal fluid of multiple sclerosis patients are specific for Epstein-Barr-virus-infected B cells
Epstein–Barr virus (EBV) infection has long been associated with multiple sclerosis (MS), but the role of EBV in the pathogenesis of MS is not clear. Our hypothesis is that a major fraction of the expanded clones of T lymphocytes in the cerebrospinal fluid (CSF) are specific for autologous EBV-infected B cells. We obtained blood and CSF samples from eight relapsing-remitting patients in the process of diagnosis. We stimulated cells from the blood with autologous EBV-infected lymphoblastoid cell lines (LCL), EBV, varicella zoster virus, influenza, and candida and sorted the responding cells with flow cytometry after 6 d. We sequenced the RNA for T cell receptors (TCR) from CSF, unselected blood cells, and the antigen-specific cells. We used the TCR Vβ CDR3 sequences from the antigen-specific cells to assign antigen specificity to the sequences from the CSF and blood. LCL-specific cells comprised 13.0 ± 4.3% (mean ± SD) of the total reads present in CSF and 13.3 ± 7.5% of the reads present in blood. The next most abundant antigen specificity was flu, which was 4.7 ± 1.7% of the reads in the CSF and 9.3 ± 6.6% in the blood. The prominence of LCL-specific reads was even more marked in the top 1% most abundant CSF clones with statistically significant 47% mean overlap with LCL. We conclude that LCL-specific sequences form a major portion of the TCR repertoire in both CSF and blood and that expanded clones specific for LCL are present in MS CSF. This has important implications for the pathogenesis of MS.
- 2 January 2023
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 70, 104497
The concentrations of antibodies to Epstein-Barr virus decrease during ocrelizumab treatment
- 2 January 2023
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 70, 104497
The concentrations of antibodies to Epstein-Barr virus decrease during ocrelizumab treatment
- Open Access
- 29 June 2022
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 28 (11) , 1729-1743
Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study
Background: Glatiramer acetate (GA) is US-approved for relapsing multiple sclerosis. Objectives: To describe GA long-term clinical profile. To compare effectiveness of early start (ES) versus delayed start (DS; up to 3 years) with GA. Methods: Phase 3 trial participants entered a randomized placebo-controlled period then an open-label extension (OLE) with GA. Results: Overall, 208 out of 251 (82.9%) randomized participants entered the OLE; 24 out of 101 (23.8%, ES) and 28 out of 107 (26.2%, DS) participants completed the OLE. Median GA treatment was 9.8 (0.1–26.3) years. Annualized change in Expanded Disability Status Scale (EDSS) score was lower with ES versus DS ( p = 0.0858: full study; p = 0.002; Year 5). Participants with improved/stable EDSS was consistently higher with ES versus DS: 40.3% versus 31.6% ( p = 0.1590; full study); 70.8% versus 55.6% ( p = 0.015; Year 5). ES prolonged time-to-6-month confirmed disease worsening (CDW) versus DS (9.8 vs 6.7 years), time-to-12-month CDW (18.9 vs 11.6 years), and significantly reduced time-to-second-6-month CDW ( p = 0.0441). No new safety concerns arose. Conclusion: GA long-term treatment maintained clinical benefit with a similar safety profile to phase 3 results; a key limitation was that only 25% of participants completed the OLE. Early initiation of GA had sustained benefits versus delayed treatment.
- 29 June 2022
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 28 (11) , 1729-1743
Open AccessEarly versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study
Background: Glatiramer acetate (GA) is US-approved for relapsing multiple sclerosis. Objectives: To describe GA long-term clinical profile. To compare effectiveness of early start (ES) versus delayed start (DS; up to 3 years) with GA. Methods: Phase 3 trial participants entered a randomized placebo-controlled period then an open-label extension (OLE) with GA. Results: Overall, 208 out of 251 (82.9%) randomized participants entered the OLE; 24 out of 101 (23.8%, ES) and 28 out of 107 (26.2%, DS) participants completed the OLE. Median GA treatment was 9.8 (0.1–26.3) years. Annualized change in Expanded Disability Status Scale (EDSS) score was lower with ES versus DS ( p = 0.0858: full study; p = 0.002; Year 5). Participants with improved/stable EDSS was consistently higher with ES versus DS: 40.3% versus 31.6% ( p = 0.1590; full study); 70.8% versus 55.6% ( p = 0.015; Year 5). ES prolonged time-to-6-month confirmed disease worsening (CDW) versus DS (9.8 vs 6.7 years), time-to-12-month CDW (18.9 vs 11.6 years), and significantly reduced time-to-second-6-month CDW ( p = 0.0441). No new safety concerns arose. Conclusion: GA long-term treatment maintained clinical benefit with a similar safety profile to phase 3 results; a key limitation was that only 25% of participants completed the OLE. Early initiation of GA had sustained benefits versus delayed treatment.
- 1 November 2021
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 56, 103282
The cellular immune response against Epstein-Barr virus decreases during ocrelizumab treatment
- 1 November 2021
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 56, 103282
The cellular immune response against Epstein-Barr virus decreases during ocrelizumab treatment
- 1 September 2017
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 310, 131-134
Antibodies to the Epstein-Barr virus proteins BFRF3 and BRRF2 cross-react with human proteins
- 1 September 2017
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 310, 131-134
Antibodies to the Epstein-Barr virus proteins BFRF3 and BRRF2 cross-react with human proteins
- 1 October 2016
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 299, 147-151
The increased antibody response to Epstein-Barr virus in multiple sclerosis is restricted to selected virus proteins
- 1 October 2016
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 299, 147-151
The increased antibody response to Epstein-Barr virus in multiple sclerosis is restricted to selected virus proteins
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
The Antibody Response to Epstein-Barr Virus in Multiple Sclerosis Is Increased Only to Selected Antigens (P5.344)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
The Antibody Response to Epstein-Barr Virus in Multiple Sclerosis Is Increased Only to Selected Antigens (P5.344)
- 1 January 2016
- Published by Elsevier in Molecular Immunology
- Vol. 69, 7-12
Antibodies specific for Epstein-Barr virus nuclear antigen-1 cross-react with human heterogeneous nuclear ribonucleoprotein L
- 1 January 2016
- Published by Elsevier in Molecular Immunology
- Vol. 69, 7-12
Antibodies specific for Epstein-Barr virus nuclear antigen-1 cross-react with human heterogeneous nuclear ribonucleoprotein L
- 4 May 2015
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 133 (1) , 17-24
Antivirus immune activity in multiple sclerosis correlates with MRI activity
The objective of this study was to determine whether reactivation of Epstein-Barr (EBV) or activation of the anti-EBV immune response correlates with MS disease activity on MR imaging. Subjects with early, active relapsing-remitting MS were studied for 16 weeks with blood and saliva samples collected every 2 weeks and brain MRI performed every 4 weeks. We isolated peripheral blood mononuclear cells from each blood sample and tested the immune response to EBV, autologous EBV-infected lymphoblastoid cell lines (LCL), human herpesvirus 6 (HHV6), varicella zoster virus (VZV), tetanus, and mitogens. We measured the proliferative response and the number of interferon-γ secreting cells with ELISPOT. We measured the amounts of EBV, HHV6, and VZV DNA in blood and saliva with quantitative PCR. On MRI, we measured number and volume of contrast enhancing and T2 lesions. We tested for correlation between the immunologic assays and the MRI results, assessing different time intervals between the MRI and immunologic assays. We studied 20 subjects. Ten had enhancing lesions on one or more MRI scans and one had new T2 lesions without enhancement. The most significant correlation was between proliferation to autologous LCL and the number of combined unique active lesions on MRI 4 weeks later. Both proliferation and number of cells secreting interferon-γ in response to LCL correlated with the number of enhancing lesions 8 weeks later. We find evidence for correlation of antiviral immune responses in the blood with subsequent disease activity on MRI scans.
- 4 May 2015
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 133 (1) , 17-24
Antivirus immune activity in multiple sclerosis correlates with MRI activity
The objective of this study was to determine whether reactivation of Epstein-Barr (EBV) or activation of the anti-EBV immune response correlates with MS disease activity on MR imaging. Subjects with early, active relapsing-remitting MS were studied for 16 weeks with blood and saliva samples collected every 2 weeks and brain MRI performed every 4 weeks. We isolated peripheral blood mononuclear cells from each blood sample and tested the immune response to EBV, autologous EBV-infected lymphoblastoid cell lines (LCL), human herpesvirus 6 (HHV6), varicella zoster virus (VZV), tetanus, and mitogens. We measured the proliferative response and the number of interferon-γ secreting cells with ELISPOT. We measured the amounts of EBV, HHV6, and VZV DNA in blood and saliva with quantitative PCR. On MRI, we measured number and volume of contrast enhancing and T2 lesions. We tested for correlation between the immunologic assays and the MRI results, assessing different time intervals between the MRI and immunologic assays. We studied 20 subjects. Ten had enhancing lesions on one or more MRI scans and one had new T2 lesions without enhancement. The most significant correlation was between proliferation to autologous LCL and the number of combined unique active lesions on MRI 4 weeks later. Both proliferation and number of cells secreting interferon-γ in response to LCL correlated with the number of enhancing lesions 8 weeks later. We find evidence for correlation of antiviral immune responses in the blood with subsequent disease activity on MRI scans.